Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
bsi-201+ topotecan · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | BSI-201 + topotecan |
| 2 | EXPERIMENTAL | BSI-201 + temozolomide |
| 3 | EXPERIMENTAL | bsi-201 + gemcitabine |
| 4 | EXPERIMENTAL | bsi-201 + carboplatin/paclitaxel |
| Iniparib | EXPERIMENTAL | - |
| Iniparib/irinotecan | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| bsi-201 + topotecan | DRUG | 21 day cycle |
| bsi-201 + temozolomide | DRUG | 28 day cycle |
| bsi-201 + gemcitabine | DRUG | 28 day cycle |
| bsi-201 + carboplatin/paclitaxel | DRUG | 21 day cycle |
| BSI-201 (iniparib) | DRUG | BSI-201 administered intravenously (IV), 2x weekly |
| irinotecan | DRUG | Irinotecan administered weekly, IV. |
Inclusion Criteria: * ≥ 18 years old with a histologically or cytologically documented, advanced solid tumor * Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1 * Absolute neutrophil count (ANC) ≥ 1.5 x 10\^9/L (without granulocyte colony-stimulating factor \[G-CSF\] support withi...
Top 20 of 45 competitors
BSI-201 is an investigational small molecule being studied for use in oncology, specifically in glioblastoma, ovarian cancer, uterine carcinosarcoma, and other tumors. It has been evaluated in clinical trials for these conditions, though it remains in clinical development and is not approved.
BSI-201 is a poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor, as indicated in the clinical trial title. It targets the PARP-1 enzyme, which is involved in DNA repair, making it a potential therapeutic approach for certain cancers.
BSI-201 is being developed by Sanofi, a global biopharmaceutical company traded on the stock exchange under the ticker SNY. Sanofi is responsible for the clinical development and potential commercialization of this investigational drug.
BSI-201 has completed Phase 1 and Phase 2 clinical trials. The most advanced studies were Phase 2, including a trial in platinum-resistant recurrent ovarian cancer. However, it is not approved and remains an investigational agent in clinical development.
BSI-201 has been studied in several completed trials, including NCT00298675, a Phase 1 dose escalation study in advanced solid tumors; NCT00422682, a Phase 1 combination study; NCT00687765, a Phase 1 study in malignant glioma; and NCT01033292, a Phase 2 study in ovarian cancer.
BSI-201 is also known as iniparib, a name that has been used in clinical research. It is a PARP-1 inhibitor that has been investigated for various cancers, including glioblastoma and ovarian cancer, though it is not approved.